Investigational drug for HER2-mutated/overexpressed/amplified cancer

Trial ID:
IRB-24-8485
Aditya R Sarvaria, MD

Inclusion Criteria

Patients must:

  • -Be 18 years of age or older.
    -Have a confirmed diagnosis of HER2 alteration on their tumor biopsy.
    -Have an available tumor biopsy sample for study testing, or are willing to undergo a new biopsy.
    -Have had at least one prior line of therapy.
    -Have the presence of at least one measurable lesion.
    -Meet all other eligibility criteria

Exclusion Criteria

Patients must not:

  • -Have had prior treatment with any HER2 tyrosine kinase inhibitors (TKIs).
    -Have another cancer malignancy, except effectively treated non-melanoma skin cancer, carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, localised prostate cancer, or other effectively treated malignancy that is considered cured by local treatment.
    -Have the presence of uncontrolled or symptomatic brain or subdural metastases during screening.
    -Have radiotherapy within 2 weeks before the start of treatment.
    - Be recovering from major surgery before screening or have major surgery planned within 6 months after screening.
    -Have a history or presence of cardiovascular abnormalities.
    -Have a cardiac ejection fraction of less than 50% within 28 days before the start of treatment.

Additional Info

All treatment and physicians' visits will take place at the Scripps Clinic Torrey Pines Geisel Pavilion or Scripps Prebys Cancer Center Mercy San Diego campus.

For more information, search NCT06581432 at www.clinicaltrails.gov

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org